ATE430127T1 - Hif hydroxylase-inhibitoren zur anämiebehandlung - Google Patents

Hif hydroxylase-inhibitoren zur anämiebehandlung

Info

Publication number
ATE430127T1
ATE430127T1 AT03712396T AT03712396T ATE430127T1 AT E430127 T1 ATE430127 T1 AT E430127T1 AT 03712396 T AT03712396 T AT 03712396T AT 03712396 T AT03712396 T AT 03712396T AT E430127 T1 ATE430127 T1 AT E430127T1
Authority
AT
Austria
Prior art keywords
hydroxylase inhibitors
hif hydroxylase
anemia treatment
treatment
activity
Prior art date
Application number
AT03712396T
Other languages
English (en)
Inventor
Christopher J Schofield
Patrick H Maxwell
Christopher W Pugh
Peter J Ratcliffe
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE430127(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE430127T1 publication Critical patent/ATE430127T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03712396T 2002-03-21 2003-03-21 Hif hydroxylase-inhibitoren zur anämiebehandlung ATE430127T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206711.4A GB0206711D0 (en) 2002-03-21 2002-03-21 HIF Inhibitor
PCT/GB2003/001239 WO2003080566A2 (en) 2002-03-21 2003-03-21 Hif hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
ATE430127T1 true ATE430127T1 (de) 2009-05-15

Family

ID=9933457

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03712396T ATE430127T1 (de) 2002-03-21 2003-03-21 Hif hydroxylase-inhibitoren zur anämiebehandlung

Country Status (13)

Country Link
US (2) US20050227948A1 (de)
EP (2) EP2065366A3 (de)
JP (1) JP2005520859A (de)
CN (6) CN101199501A (de)
AT (1) ATE430127T1 (de)
AU (2) AU2003216857B2 (de)
CA (1) CA2479881A1 (de)
DE (1) DE60327428D1 (de)
ES (1) ES2322992T3 (de)
GB (1) GB0206711D0 (de)
MX (1) MXPA04009155A (de)
PL (1) PL205110B1 (de)
WO (1) WO2003080566A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US20050170019A1 (en) * 2003-10-22 2005-08-04 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
WO2005039291A2 (en) * 2003-10-22 2005-05-06 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
JP2007530522A (ja) * 2004-03-26 2007-11-01 アイシス・イノベーション・リミテッド アッセイ
PL1676591T3 (pl) * 2004-11-24 2018-12-31 Lifescan, Inc. Kompozycje i sposoby tworzenia unaczynionego środowiska dla przeszczepu komórkowego
PT1879599E (pt) * 2005-04-20 2014-01-23 Hutchinson Fred Cancer Res Métodos, composições e artigos de fabrico para aumentar a capacidade de sobrevivência de células, tecidos, órgãos, e organismos
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
GB0519605D0 (en) 2005-09-26 2005-11-02 Isis Innovation Assay
EP2044028B1 (de) 2006-01-27 2012-05-16 Fibrogen, Inc. Cyanoisochinoline zur stabilisierung des hypoxie-induzierten faktors (hif)
RU2461557C2 (ru) 2006-04-04 2012-09-20 Файброджен, Инк. Соединения пирроло- и тиазолопиридина (варианты) и фармацевтическая композиция на их основе
JP2010524935A (ja) * 2007-04-18 2010-07-22 メルク・シャープ・エンド・ドーム・コーポレイション 新規１，８−ナフチリジン化合物
AU2008319229A1 (en) * 2007-11-02 2009-05-07 Fibrogen, Inc. Methods for reducing blood pressure
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
WO2009134847A1 (en) * 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
GB0809262D0 (en) 2008-05-21 2008-06-25 Isis Innovation Assay
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
NZ592741A (en) 2008-11-14 2013-03-28 Fibrogen Inc Thiochromene derivatives as hif hydroxylase inhibitors
AU2011235212B2 (en) 2010-03-31 2014-07-31 The Scripps Research Institute Reprogramming cells
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
CN104427980A (zh) * 2012-03-09 2015-03-18 菲布罗根有限公司 高胆固醇的治疗
TWI685487B (zh) 2013-01-24 2020-02-21 美商費比羅根公司 ｛［１-氰基-５-（４-氯苯氧基）-４-羥基-異喹啉-３-羰基］-胺基｝-乙酸之晶形
CA3009350A1 (en) * 2016-01-05 2017-07-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for regulating activity of inhibitor of dna binding-2 (id2) protein
WO2018232227A1 (en) * 2017-06-15 2018-12-20 The Trustees Of Columbia University In The City Of New York Treatment of neurodegeneration via reprogramming metabolism by inhibiting phd
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
EP4347022A1 (de) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pädiatrische formulierungen von eisencitrat

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620359A1 (de) 1965-12-10 1969-12-18 Norddeutsche Affinerie Wachstumbeeinflussende Mittel
AT279048B (de) 1967-07-04 1970-02-25 Pharmazeutische Fabrik Montavit Gmbh Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon
FR6969M (de) 1968-05-19 1969-05-19
US4273779A (en) * 1976-12-23 1981-06-16 Ciba-Geigy Corporation Treating hypertension with substituted-5-amino-2-pyridinecarboxylic acids
JPS5754151A (en) * 1980-09-18 1982-03-31 Takeda Chem Ind Ltd Physiologically active substance b-52653 and its preparation
JPS5899453A (ja) * 1981-12-10 1983-06-13 Mitsubishi Chem Ind Ltd オリゴペプチド
US4446038A (en) * 1982-09-27 1984-05-01 Texaco, Inc. Citric imide acid compositions and lubricants containing the same
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
ATE49214T1 (de) 1984-12-17 1990-01-15 American Cyanamid Co Platinkomplexe von aliphatischen tricarbonsaeuren.
JPS61218522A (ja) 1985-03-22 1986-09-29 Sachimaru Senoo 中性乃至弱アルカリ性で安定な水酸化鉄コロイド溶液
JPS61249993A (ja) 1985-04-26 1986-11-07 Tanabe Seiyaku Co Ltd 新規有機白金錯体及びその製法
US4752602A (en) 1985-09-09 1988-06-21 Board Of Regents, The University Of Texas System Dipeptide alkyl esters and their uses
DE3544338A1 (de) * 1985-12-14 1987-06-19 Hoechst Ag Peptid-derivate mit inhibitorischer wirkung auf hydroxylierende enzyme, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
FR2662359A1 (fr) 1986-04-18 1991-11-29 Flork Michel Nouveaux peptides diuretiques et natriuretiques.
CH673459A5 (de) 1987-05-15 1990-03-15 Eprova Ag
DE3818850A1 (de) * 1988-06-03 1989-12-07 Hoechst Ag Oligopeptide mit zyklischen prolin-analogen aminosaeuren
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
RU2001588C1 (ru) 1992-05-07 1993-10-30 Феликс Семенович Ройтман Сок с м котью
JP3595352B2 (ja) 1993-02-01 2004-12-02 株式会社サンギ 抗腫瘍剤及び抗菌剤
DE4410453A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
WO1997024145A1 (fr) * 1995-12-28 1997-07-10 Daiichi Radioisotope Laboratories, Ltd. Medicaments d'aide au diagnostic
RU2079307C1 (ru) 1996-07-08 1997-05-20 Михаил Александрович Каплан Противоанемическое средство
RU2111746C1 (ru) 1996-07-31 1998-05-27 Всероссийский научный центр по безопасности биологически активных веществ Водный раствор, обладающий гепатопротекторным действием
US5972894A (en) * 1997-08-07 1999-10-26 Cytran, Inc. Peptides having potassium channel opener activity
US6200974B1 (en) * 1997-10-24 2001-03-13 Zeneca Limited Phenanthroline derivatives
RU2141943C1 (ru) 1998-11-27 1999-11-27 Научно-исследовательский институт фармакологии при Волгоградской медицинской академии Динатриевая соль n-ацетил-l-аспарагиновой кислоты, обладающая антидепрессантной и ноотропной активностью
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
ATE383877T1 (de) * 1999-06-04 2008-02-15 Dana Farber Cancer Inst Inc Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren
GB0013655D0 (en) 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
AU2002241154A1 (en) * 2001-03-21 2002-10-03 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase

Also Published As

Publication number Publication date
CA2479881A1 (en) 2003-10-02
AU2003216857A1 (en) 2003-10-08
AU2009202216A1 (en) 2009-06-25
EP1485347B1 (de) 2009-04-29
EP2065366A2 (de) 2009-06-03
JP2005520859A (ja) 2005-07-14
ES2322992T3 (es) 2009-07-03
US7662854B2 (en) 2010-02-16
PL205110B1 (pl) 2010-03-31
CN101199512A (zh) 2008-06-18
US20070066576A1 (en) 2007-03-22
CN100369891C (zh) 2008-02-20
MXPA04009155A (es) 2004-11-26
CN101199502A (zh) 2008-06-18
CN101199503A (zh) 2008-06-18
WO2003080566A2 (en) 2003-10-02
CN101199501A (zh) 2008-06-18
WO2003080566A3 (en) 2003-12-11
EP2065366A3 (de) 2009-09-02
CN101199537A (zh) 2008-06-18
PL371515A1 (en) 2005-06-27
DE60327428D1 (de) 2009-06-10
AU2003216857B2 (en) 2009-06-11
GB0206711D0 (en) 2002-05-01
CN1653040A (zh) 2005-08-10
EP1485347A2 (de) 2004-12-15
US20050227948A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
DE60327428D1 (de) Hif hydroxylase-inhibitoren zur anämiebehandlung
HK1173721A1 (en) 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2- amino-propionic acid amides and related compounds having analgesic and or immunostimulant activity 3--3--2-3-- 3--2--
HK1113056A1 (en) Nicotinamide derivates useful as p38 inhibitors
ATE510534T1 (de) Naltrexonhydrochlorid-zusammensetzungen
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
DE602004017037D1 (de) 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
EP1596854A4 (de) Behandlung von erkrankungen im zusammenhang mit verringerter stickoxid-bioverfügbarkeit, einschliesslich erhöhte arginase
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
EE05417B1 (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
DE60332163D1 (de) Zusammensetzung zur hautaufhellung
IL174210A0 (en) 1,4 disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
SE0203752D0 (sv) New compounds
MY140031A (en) Carbonyl compounds
LU91935I9 (de)
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE550013T1 (de) Zink-konservierungszusammensetzung und anwendungsverfahren
ATE434607T1 (de) 1-(4-amino-cyclohexyl)-1,3-dihydro-2h- benzimidazole-2-on derivate und verwandte verbindungen als nociceptin analoge und orl1 liganden zur behandlung von schmerz
DE60332096D1 (de) Mikrosatellitenmarker in form von mononukleotidwiederholungen zur detektion von mikrosatelliteninstabilität
ATE555674T1 (de) Zusammensetzung mit der reduzierten form von coenzym q10 und carotenoid-verbindung
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
MXPA05013251A (es) Composiciones para estado de oxigeno mejorado en animales de compania.
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
NO20053903D0 (no) Nukleotidlipidesterderivater.
ATE519380T1 (de) Unterstützung der kognitiven funktion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties